Biolargo Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Biolargo has an operating margin of -24.4%, meaning the company retains $-24 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -37.5% the prior year.
Biolargo's revenue surged 45.4% year-over-year to $17.8M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Biolargo carries a low D/E ratio of 0.12, meaning only $0.12 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.70, Biolargo holds $2.70 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 88/100.
Biolargo passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Biolargo generates $0.74 in operating cash flow (-$3.2M OCF vs -$4.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Biolargo earns $-65.6 in operating income for every $1 of interest expense (-$4.3M vs $66K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Biolargo (BLGO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Biolargo generated $17.8M in revenue in fiscal year 2024. This represents an increase of 45.4% from the prior year.
Biolargo's EBITDA was -$4.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 6.7% from the prior year.
Biolargo reported -$4.3M in net income in fiscal year 2024. This represents an increase of 6.5% from the prior year.
Biolargo held $3.5M in cash against $1.1M in long-term debt as of fiscal year 2024.
Biolargo's gross margin was 44.2% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 6.2 percentage points from the prior year.
Biolargo's operating margin was -24.4% in fiscal year 2024, reflecting core business profitability. This is up 13.1 percentage points from the prior year.
Biolargo's net profit margin was -24.4% in fiscal year 2024, showing the share of revenue converted to profit. This is up 13.6 percentage points from the prior year.
Biolargo invested $2.9M in research and development in fiscal year 2024. This represents an increase of 26.3% from the prior year.
BLGO Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M-60.3% | $2.8M-15.1% | $3.3M-10.5% | $3.7M-27.1% | $5.0M+5.3% | $4.8M+8.9% | $4.4M+63.5% | $2.7M |
| Cost of Revenue | $731K-46.1% | $1.4M-23.9% | $1.8M-6.6% | $1.9M-33.8% | $2.9M+14.4% | $2.5M+10.3% | $2.3M+84.3% | $1.2M |
| Gross Profit | $372K-73.8% | $1.4M-4.5% | $1.5M-14.9% | $1.7M-18.2% | $2.1M-4.9% | $2.2M+7.5% | $2.1M+45.6% | $1.4M |
| R&D Expenses | $615K+15.0% | $535K-32.4% | $791K+0.8% | $785K+26.0% | $623K-20.5% | $784K+79.8% | $436K-37.2% | $694K |
| SG&A Expenses | $3.1M+14.9% | $2.7M+5.0% | $2.6M-0.8% | $2.6M+7.3% | $2.4M+8.0% | $2.2M-1.9% | $2.3M-0.5% | $2.3M |
| Operating Income | -$7.2M-298.4% | -$1.8M+3.2% | -$1.9M-15.2% | -$1.6M-81.7% | -$890K-16.6% | -$763K+24.2% | -$1.0M+34.5% | -$1.5M |
| Interest Expense | $144K+80.0% | $80K+23.1% | $65K+66.7% | $39K+1850.0% | $2K-83.3% | $12K-36.8% | $19K+58.3% | $12K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$7.2M-284.9% | -$1.9M+2.0% | -$1.9M-10.9% | -$1.7M-122.1% | -$780K-0.6% | -$775K+24.0% | -$1.0M+32.4% | -$1.5M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BLGO Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $9.1M-27.0% | $12.5M+18.9% | $10.5M0.0% | $10.5M+4.6% | $10.1M+2.4% | $9.8M+19.7% | $8.2M+25.4% | $6.5M |
| Current Assets | $5.8M-37.1% | $9.2M+27.3% | $7.2M+1.1% | $7.1M+0.4% | $7.1M-0.9% | $7.2M+12.8% | $6.4M+35.6% | $4.7M |
| Cash & Equivalents | $4.5M+31.0% | $3.5M+35.4% | $2.6M-27.7% | $3.5M-25.5% | $4.8M+9.9% | $4.3M+22.5% | $3.5M+16.3% | $3.0M |
| Inventory | $409K-7.9% | $444K+20.3% | $369K+11.8% | $330K+87.5% | $176K-29.9% | $251K+64.1% | $153K+25.4% | $122K |
| Accounts Receivable | $761K-56.1% | $1.7M-58.8% | $4.2M+32.8% | $3.2M+50.6% | $2.1M-14.9% | $2.5M-5.3% | $2.6M+79.8% | $1.5M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.5M-60.4% | $6.4M+18.8% | $5.4M+226.2% | $1.7M-60.1% | $4.2M+143.9% | $1.7M+25.3% | $1.4M+359.7% | -$524K |
| Current Liabilities | $3.5M-15.4% | $4.1M+21.0% | $3.4M+27.4% | $2.6M-12.1% | $3.0M-11.5% | $3.4M+25.6% | $2.7M+55.7% | $1.7M |
| Long-Term Debt | N/A | N/A | N/A | $1.1M+486.4% | $184K-35.2% | $284K-1.7% | $289K-1.4% | $293K |
| Total Equity | $6.6M-24.8% | $8.8M+15.1% | $7.6M-14.0% | $8.9M+47.5% | $6.0M-26.0% | $8.1M+18.6% | $6.8M-3.2% | $7.1M |
| Retained Earnings | -$158.3M-4.3% | -$151.8M-0.8% | -$150.7M-0.8% | -$149.5M-1.0% | -$147.9M-0.3% | -$147.5M-0.3% | -$147.1M-0.5% | -$146.4M |
BLGO Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.8M-30.3% | -$2.1M-15.7% | -$1.8M+4.5% | -$1.9M-1168.9% | -$151K-131.4% | $481K+24150.0% | -$2K+99.8% | -$836K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $256K+33.3% | $192K | $0+100.0% | -$57K+84.1% | -$358K+58.5% | -$863K-491.1% | -$146K+28.8% | -$205K |
| Financing Cash Flow | $3.6M+26.0% | $2.8M+227.1% | $866K-45.6% | $1.6M+59.4% | $999K-7.8% | $1.1M+42.3% | $761K+50.1% | $507K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BLGO Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 33.7%-17.4pp | 51.2%+5.7pp | 45.5%-2.3pp | 47.8%+5.2pp | 42.6%-4.6pp | 47.2%-0.7pp | 47.8%-5.9pp | 53.7% |
| Operating Margin | -651.0%-586.1pp | -64.9%-7.9pp | -57.0%-12.7pp | -44.3%-26.5pp | -17.8%-1.7pp | -16.0%+7.0pp | -23.0%+34.5pp | -57.5% |
| Net Margin | -656.8%-589.0pp | -67.8%-9.0pp | -58.8%-11.4pp | -47.4%-31.8pp | -15.6%+0.7pp | -16.3%+7.1pp | -23.3%+33.1pp | -56.4% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -79.3%-64.3pp | -15.1%+3.2pp | -18.3%-1.8pp | -16.5%-8.7pp | -7.8%+0.1pp | -7.9%+4.5pp | -12.4%+10.6pp | -23.0% |
| Current Ratio | 1.67-0.6 | 2.25+0.1 | 2.14-0.6 | 2.70+0.3 | 2.36+0.3 | 2.11-0.2 | 2.35-0.3 | 2.70 |
| Debt-to-Equity | 0.39-0.3 | 0.74+0.0 | 0.71+0.6 | 0.12+0.1 | 0.030.0 | 0.040.0 | 0.040.0 | 0.04 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Biolargo's annual revenue?
Biolargo (BLGO) reported $17.8M in total revenue for fiscal year 2024. This represents a 45.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Biolargo's revenue growing?
Biolargo (BLGO) revenue grew by 45.4% year-over-year, from $12.2M to $17.8M in fiscal year 2024.
Is Biolargo profitable?
No, Biolargo (BLGO) reported a net income of -$4.3M in fiscal year 2024, with a net profit margin of -24.4%.
What is Biolargo's EBITDA?
Biolargo (BLGO) had EBITDA of -$4.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Biolargo have?
As of fiscal year 2024, Biolargo (BLGO) had $3.5M in cash and equivalents against $1.1M in long-term debt.
What is Biolargo's gross margin?
Biolargo (BLGO) had a gross margin of 44.2% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Biolargo's operating margin?
Biolargo (BLGO) had an operating margin of -24.4% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Biolargo's net profit margin?
Biolargo (BLGO) had a net profit margin of -24.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Biolargo's operating cash flow?
Biolargo (BLGO) generated -$3.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Biolargo's total assets?
Biolargo (BLGO) had $10.5M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Biolargo spend on research and development?
Biolargo (BLGO) invested $2.9M in research and development during fiscal year 2024.
What is Biolargo's current ratio?
Biolargo (BLGO) had a current ratio of 2.70 as of fiscal year 2024, which is generally considered healthy.
What is Biolargo's debt-to-equity ratio?
Biolargo (BLGO) had a debt-to-equity ratio of 0.12 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Biolargo's return on assets (ROA)?
Biolargo (BLGO) had a return on assets of -41.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Biolargo's cash runway?
Based on fiscal year 2024 data, Biolargo (BLGO) had $3.5M in cash against an annual operating cash burn of $3.2M. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Biolargo's Piotroski F-Score?
Biolargo (BLGO) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biolargo's earnings high quality?
Biolargo (BLGO) has an earnings quality ratio of 0.74x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Biolargo cover its interest payments?
Biolargo (BLGO) has an interest coverage ratio of -65.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Biolargo?
Biolargo (BLGO) scores 72 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.